Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and...
Bill Humphries, CEO of Alcami, shares his vision for the future, discussing dynamic market trends and the company’s commitment to innovation. Under his leadership, Alcami...
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine...
Cambridge, Leiden, Heidelberg or Paris - many European countries have biotechnology clusters in which scientific expertise meets a well-developed infrastructure...
Consulting firm BCG has evaluated the effectiveness of biotech innovation centers in Europe and the USA. Adolphs explains what is lacking in Germany in particular.
Lonza recently announced that it has completed a planned expansion of the mid-scale microbial manufacturing facility at its Visp, Switzerland site. This multi-product...
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
